BRIC countries' breast cancer market to see 8% annual growth to 2017
The market for breast cancer therapies in the BRIC countries (Brazil, Russia, India and China) will grow 8% annually over the next five years, from $1.7 billion in 2012 to $2.5 billion in 2017, according to a new report from health care advisory firm Decision Resources. The market’s growth can be attributed to the launch of several premium priced agents, a gradual increase in the use of targeted therapies and a rise in the incident population.
According to the Emerging Markets report, titled Breast Cancer in the BRIC Markets, the Brazilian breast cancer market is currently the largest of the BRIC and accounts for 50% of the total market share for breast cancer therapies. However, while these market shares will remain consistent, the Chinese market is anticipated to develop the most through 2017.
Greatest growth expected in China
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze